Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The inflammation: lipoprotein cycle.

Philip Barter1

  • 1The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia. p.barter@hri.org.au

Atherosclerosis. Supplements
|April 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region.

Lipids in health and disease·2021
Same author

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity.

Nature reviews. Endocrinology·2020
Same author

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.

The lancet. Diabetes & endocrinology·2019
Same author

HDL cholesterol and ASCVD risk stratification: A debate.

Atherosclerosis·2019
Same author

Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East.

International journal of general medicine·2018
Same author

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.

Circulation·2018
Same journal

'Diet and lifestyle' in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members.

Atherosclerosis. Supplements·2021
Same journal

Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool.

Atherosclerosis. Supplements·2021
Same journal

Lipid Clinics Network. Rationale and design of the EAS global project.

Atherosclerosis. Supplements·2021
Same journal

Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives.

Atherosclerosis. Supplements·2021
Same journal

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.

Atherosclerosis. Supplements·2021
Same journal

Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies.

Atherosclerosis. Supplements·2021
See all related articles

Low-density lipoproteins (LDLs) promote atherosclerosis by initiating arterial inflammation, while high-density lipoproteins (HDLs) protect against it. Therapies targeting both lipid levels and inflammation, like statins and HDL-boosting treatments, are key for effective atherosclerosis prevention.

Area of Science:

  • Cardiovascular Biology
  • Lipid Metabolism
  • Inflammation Research

Background:

  • Lipoproteins critically influence atherosclerosis development and progression.
  • Low-density lipoproteins (LDLs) and remnant lipoproteins are atherogenic, whereas high-density lipoproteins (HDLs) are protective.
  • Lipoprotein's impact on inflammation is central to atherogenesis.

Purpose of the Study:

  • To elucidate the dual roles of lipoproteins in atherosclerosis, focusing on their inflammatory effects.
  • To highlight the anti-inflammatory mechanisms of high-density lipoproteins (HDLs).
  • To evaluate the comprehensive anti-atherosclerotic potential of statins and novel HDL-targeting therapies.

Main Methods:

  • Review of established knowledge on lipoprotein function in atherosclerosis.

Related Experiment Videos

  • Analysis of mechanisms by which modified LDLs initiate arterial inflammation.
  • Examination of HDL-mediated reversal of inflammation, including cholesterol efflux and oxidation inhibition.

    • Main Results:

    • Modified LDLs trigger inflammatory processes in the arterial wall, leading to lesion development.
    • HDLs counteract inflammation through cholesterol efflux, LDL oxidation inhibition, and reduced adhesion molecule expression.
    • Statins exhibit anti-inflammatory effects via lipid-dependent and -independent pathways.

    Conclusions:

    • Effective atherosclerosis treatment requires addressing both lipid profiles and inflammation.
    • Statins offer dual benefits by modifying lipids and reducing inflammation.
    • Enhancing HDL levels and activity presents a promising strategy for additional atherosclerotic protection.